Literature DB >> 2440951

Regulation of hepatic acute phase protein synthesis by products of interleukin 2 (IL 2)-stimulated human peripheral blood mononuclear cells.

J W Mier, C A Dinarello, M B Atkins, P I Punsal, D H Perlmutter.   

Abstract

Cancer patients injected with recombinant human IL 2 develop marked changes in serum concentrations of hepatic acute-phase proteins. To determine if this acute-phase response involves a change in the rate of hepatic protein synthesis and if it is due to a direct effect of IL 2 on hepatocytes, human hepatoma-derived hepatocytes (Hep-3B cells) were incubated in medium containing IL 2 or in culture supernatants from IL 2-activated human peripheral blood mononuclear cells (PBMNC). The rate of synthesis of two acute-phase proteins, complement protein factor B and albumin, was determined by the incorporation of a radiolabeled amino acid precursor into newly synthesized protein as measured by analytical gel electrophoresis of immunoprecipitates. IL 2 in concentrations from 1 to 1000 U/ml had no effect on the synthesis of factor B or albumin; conversely, there was a dose-dependent increase in the rate of synthesis of factor B and decrease in albumin synthesis mediated by culture supernatants of IL 2-activated PBMNC. The magnitude of the effect of acute-phase protein synthesis was dependent on the IL 2 concentration used for the activation of PBMNC. The rate of factor B synthesis increased approximately 4.0-fold in the presence of culture supernatants of PBMNC activated with either opsonized heat-killed Staphylococcus albus or with 1000 U/ml IL 2. Preincubation of the IL 2-activated PBMNC culture supernatants with an antiserum specific for recombinant IL 1-beta completely neutralized the capacity of the supernatants to stimulate factor B synthesis, whereas antisera specific for human IL 1-alpha or for tumor necrosis factor had no effect. These results indicate that the indirect effect of IL 2 on hepatic acute phase protein synthesis is mediated by IL 1-beta.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440951

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients.

Authors:  J W Mier; G Vachino; J W van der Meer; R P Numerof; S Adams; J G Cannon; H A Bernheim; M B Atkins; D R Parkinson; C A Dinarello
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

2.  Cellular specificity of murine renal C3 expression in two models of inflammation.

Authors:  B H Ault; H R Colten
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

Review 3.  Infectious diseases associated with complement deficiencies.

Authors:  J E Figueroa; P Densen
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

4.  Interleukin 2 mediates stimulation of complement C3 biosynthesis in human proximal tubular epithelial cells.

Authors:  R A Brooimans; A P Stegmann; W T van Dorp; A A van der Ark; F J van der Woude; L A van Es; M R Daha
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

Review 5.  Human inborn errors of immunity to infection affecting cells other than leukocytes: from the immune system to the whole organism.

Authors:  Shen-Ying Zhang; Emmanuelle Jouanguy; Qian Zhang; Laurent Abel; Anne Puel; Jean-Laurent Casanova
Journal:  Curr Opin Immunol       Date:  2019-05-20       Impact factor: 7.486

6.  Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.

Authors:  Brendan Curti; Gregory A Daniels; David F McDermott; Joseph I Clark; Howard L Kaufman; Theodore F Logan; Jatinder Singh; Meenu Kaur; Theresa L Luna; Nancy Gregory; Michael A Morse; Michael K K Wong; Janice P Dutcher
Journal:  J Immunother Cancer       Date:  2017-12-19       Impact factor: 13.751

7.  Pure Red Cell Aplasia Following Interleukin-2 Therapy.

Authors:  Janice P Dutcher; Wen Fan; Peter H Wiernik
Journal:  J Investig Med High Impact Case Rep       Date:  2016-04-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.